Access to this article is restricted until 12 months after publication by request of the publisher.. Restriction lift date: 2021-05-21
APPEAL‐1: A pan-European survey of patient/caregiver perceptions of peanut allergy management
Loading...
Files
Accepted Version
Supporting Information
Date
2020-05-21
Authors
Blumchen, Katharina
Dunn Galvin, Audrey
Timmermans, Frans
Regent, Lynne
Schnadt, Sabine
Podestà, Marcia
Sánchez, Angel
Couratier, Pascale
Feeney, Mary
Hjorth, Betina
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Inc.
Published Version
Abstract
Background: Peanut allergy (PA) is associated with marked quality‐of‐life (QoL) impairment. However, data are lacking on the experience and impact of living with PA from the perspectives of persons with PA (PwPA) and their caregivers. A llergy to P eanuts imP acting E motions A nd L ife study 1 (APPEAL‐1) was a pan‐European survey investigating these perspectives. This first of two articles reports clinical characteristics of PwPA and PA management practices. Methods: APPEAL‐1 was a quantitative, online survey conducted in eight European countries, developed by eight representatives of patient advocacy groups and five healthcare professionals and researchers. Eligible participants included adults with PA and parents/caregivers of PwPA who responded by self‐report and provided proxy‐report for the PwPA under their care. Data were summarised using nonweighted descriptive statistics. Results: Of 1846 completed/analysed questionnaires, 528 were from adults with PA (self‐report); 437 by proxy for children with PA (34 aged 0‐3 years, 287 aged 4‐12 years, 116 aged 13‐17 years); 881 from parents/caregivers (self‐report). Of PwPA (N=965), 95% reported diagnosis by healthcare professionals, mostly by clinical history and peanut‐specific allergy testing. Rates of allergic rhinitis, asthma, and other food allergies in PwPA were 50%, 42%, and 79%, respectively. Only 31% of PwPA received HCP advice/support following their worst allergic reaction, and 28% had not been prescribed an adrenaline auto‐injector. Results were similar by country but varied by age group. Conclusions: The APPEAL‐1 findings contribute to greater understanding of PA impact on PwPA, caregivers, and family members and the need for improved PA management across Europe.
Description
Keywords
Clinical history , Diagnosis , Europe , Peanut allergy , Quality of life
Citation
Blumchen, K., Dunn Galvin, A., Timmermans, F., Regent, L., Schnadt, S., Podestà, M., Sánchez, A., Couratier, P., Feeney, M., Hjorth, B., Patel, R., Lush, T., Ryan, R., Vereda, A., Fisher, H.R. and Fernández‐Rivas, M. (2020) ‘APPEAL‐1: A pan-European survey of patient/caregiver perceptions of peanut allergy management’, Allergy. doi: 10.1111/all.14414
Link to publisher’s version
Copyright
© 2020, John Wiley & Sons, Inc. This is the peer reviewed version of the following article: Blumchen, K., Dunn Galvin, A., Timmermans, F., Regent, L., Schnadt, S., Podestà, M., Sánchez, A., Couratier, P., Feeney, M., Hjorth, B., Patel, R., Lush, T., Ryan, R., Vereda, A., Fisher, H.R. and Fernández‐Rivas, M. (2020) ‘APPEAL‐1: A pan‐European survey of patient/caregiver perceptions of peanut allergy management’, Allergy, doi: 10.1111/all.14414, which has been published in final form at https://doi.org/10.1111/all.14414. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.